@article{open2681,
          volume = {32},
          number = {2},
           month = {May},
          author = {Yogendra S Rathore and Jinal Shukla and BR Mittal and G Singh and K. Gopal and R Kumar and Amanjit Bal and I Laroiya and T Lakhanpal},
            note = {The copyright of this article belongs to ELSEVIER},
           title = {Radiolabelled trastuzumab Fab as a theranostic molecule for HER2 positive breast cancers
},
       publisher = {ELSEVIER},
            year = {2021},
         journal = {ANNALS OF ONCOLOGY},
             url = {http://crdd.osdd.net/open/2681/},
        abstract = {nherited genes, hormonal imbalance, environmental factors, and mutation in genes are responsible for the development of breast cancer in females. Nowadays, passive immunotherapy is used to combat cancer. Trastuzumab is a humanized monoclonal antibody (mAb) and has a pronounced effect when used as adjuvant therapy, but high doses (4-8 mg/kg) and greater molecular weight (MW) increases liver retention. To fill this hiatus, antibody fragments (Fab) are generated and showed similar target specificity. The radiolabelling of Fab may provide the theranostic application in breast cancer patients.}
}